Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.38 |
| ▸ | CA2 | P00918 | 11/20 | 0.38 |
| ▸ | CA12 | O43570 | 7/20 | 0.35 |
| ▸ | CA9 | Q16790 | 7/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 5/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18360481 | 0.88 | CA1 (0.36) | CA1CA2CA12CA9BTK | |
| SCHEMBL18354113 | 0.76 | LMNA (0.46) | CA1CA2CA12CA9BTK | |
| SCHEMBL4784090 | 0.73 | HPGD (0.48) | F2MAPTHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL18354781 | 0.72 | NPC1 (0.49) | MAPTHPGDKMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL18354523 | 0.72 | NPC1 (0.59) | CA1CA2CA12CA9 | |
| SCHEMBL18354766 | 0.72 | CA1 (0.48) | CA1CA2CA12CA9 | |
| SCHEMBL18354112 | 0.71 | KMT2A (0.48) | CA1CA2CA12CA9MAPT | |
| SCHEMBL18360452 | 0.71 | ALPL (0.54) | CA1CA2CA12CA9MAPT | |
| SCHEMBL18360449 | 0.71 | CA1 (0.41) | CA1CA2CA12CA9KMT2A | |
| SCHEMBL18354524 | 0.71 | MEN1 (0.40) | CA1CA2CA12CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170000133-A1 | BENZOXABOROLE FUNGICIDES | SYNGENTA PARTICIPATIONS AG (SE) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170000133-A1 | BENZOXABOROLE FUNGICIDES | CYP4X1, BROX, CYP1B1 | CA1 3964/4885CA2 1649/4885CA12 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.